Oferta Tecnológica

New topical treatment for HPV

  • Therapy

Viral warts are caused by the human papillovirus (HPV) and consist in an extremely high prevalence pathology among the general population. Most HPV infections are asymptomatic, but when they do produce symptoms, they cause the formation of warts (epithelial formations on the skin and mucosa). It is known that in many cases spontaneous involution of the warts occur at a rate of approximately 50% in the first year and 93% in five years. However, the involution time is unpredictable and warts can be contagious, cause discomfort (pain, itching, bleeding, etc.) and are unsightly. For these reasons, they are usually treated without waiting for the involution to occur.

There are currently no specific antivirals available for HPV, and the treatment consists in the use of abrasive or keratolytic techniques, that intent to destroy the infected tissue, even though the surrounding healthy tissue is also going to be affected, or immunomodulatory techniques, to stimulate the immune system to destroy the infected tissue. Furthermore, there is no scientific evidence as to which is the best treatment option. This highlights the need of new effective therapeutic alternatives to be found that could be capable of eliminating the mucocutaneous lesions by acting specifically against the virus while affecting only minimally the non-infected surrounding tissue.

This technology involves the use of the pyrophosphate as a topical medication for the treatment of mucocutaneous infections caused by HPV. These compounds selectively inhibit the polymerase of the viral DNA and viral transcriptase at the binding site with pyrophosphate. Studies carried out have demonstrated its effectiveness, with high cure rates even in cases of recalcitrant warts with no significant side effects.


  • Effective antiviral when applied topically.

  • The treatment is painless and easy to apply.

  • Minimal or non irritation associated with its use.

  • Demonstrated high rate of

  • Specific antiviral action as it is an antiviral agent, rather than having a merely “destructive” or immunomodulatory effect, which is what standard methods tend to produce.

  • The treatment’s production has low cost compared with other topical antiviral agents or immunomodulators used.

Palabras Clave


  • Infectious diseases


Isabel Guerrero

Unidad de Innovación IBIMA
+34 951 440 260 ext.: 205 +34 671 534 901 Corp.: 63 49 01 isabel.guerrero@ibima.eu

María Mengual

Unidad de Innovación IBIMA
+34 951 440 260 ext.: 205 +34 689 008 050 maria.mengual@ibima.eu


Suscríbete a nuestro Newsletter y recibe en tu correo todas las últimas novedades del Instituto.
Consulta el histórico de Newsletter:

Calle Doctor Miguel Díaz Recio , 28 Málaga 29010

(+34) 951 440 260
Fax: (+34) 951 440 263